Novel systemic therapies for breast cancer

Surgical Oncology

Volumn 12, Issue 4, 2003, Pages 277-287

  Lo, Soo ^a   Johnston, Stephen R D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; Growth factor receptors; Resistance; Signal transduction inhibitors

Indexed keywords

4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; 7 HYDROXYSTAUROSPORINE; ACOLBIFENE; ANASTROZOLE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ARZOXIFENE; CANCER VACCINE; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; DOXORUBICIN; DROLOXIFENE; ERLOTINIB; FLAVOPIRIDOL; FULVESTRANT; GEFITINIB; IDOXIFENE; IMATINIB; LONAFARNIB; MIPROXIFENE PHOSPHATE; NAVELBINE; PACLITAXEL; PIPENDOXIFENE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TIPIFARNIB; TOREMIFENE; TRASTUZUMAB; UNINDEXED DRUG;

ALOPECIA; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG COATING; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; METASTASIS; METASTASIS INHIBITION; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; STRUCTURE ACTIVITY RELATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; BIOPSY, NEEDLE; BREAST NEOPLASMS; CANCER VACCINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1442360019     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2003.11.001     Document Type: Review

References (60)

1. Perez E. Current management of metastatic breast cancer. Semin Oncol. 26(Suppl. 12):1990;110.
2. Cold S., Jensen N.V., Brinkcker H.et al. The influence of chemotherapy on survival after recurrence in breast cancer. a population based study of patients treated in the 1950s, 1960s, and 1970s Eur J Cancer. 29:1993;1146-1152.
3. Johnston S.R.D. Acquired tamoxifen resistance in human breast cancer; potential mechanisms and clinical implications. Anticancer Drugs. 8:1997;911-930.
4. Howell A., DeFriend D.et al. Response to a specific antiestrogen (ICI182,780) intamoxifen-resistant breast cancer. Lancet. 345:1995;29-30.
5. Osborne C.K., Pippen J., Jones S.E.et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy. results of a North American trial J Clin Oncol. 20:2002;3386-3395.
6. Howell A., Robertson J.F.R., Quaresma Albano J.et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 20:2002;3396-3403.
7. ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer; first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
8. Nabholtz J.M., Buzdar A., Pollack M.et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast carcinoma in postmenopausal women; results of a North American multicenter randomised trial. J Clin Oncol. 18:2000;3758-3767.
9. Mouridsen H., Gershanovich M., Sun Y.et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in post-menopausal women. analysis of survival and update of efficacy from international letrozole breast cancer group J Clin Oncol. 21:2003;2101-2109.
10. Jeng M.H., Shupnik M.A., Bender T.P.et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology. 139:1998;4164-4174.
11. Martin L-.A., Farmer I., Johnston S.R.D., Ali S., Marshall C., Dowsett M. Enhanced ER-alpha, ERB2 and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long-term estrogen deprivation. J Biol Chem. 278:2003;30458-30468.
12. Steger G, Bartsch R, Wenzel C, et al. Fulvestrant beyond the second hormonal treatment line in metastatic breast cancer. Proc Am Soc Clin Oncol 2003;22:20 (Abstract 78).
13. Perey L, Thürlimann B, Hawle H, et al. Fulvestrant ('faslodex') as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors. Breast Cancer Res Treat 2002;76(Suppl. 1):S72 (Abstract 249).
14. Johnston S.R.D. Endocrine manipulation in advanced breast cancer; recent advances with SERM therapies. Clin Cancer Res. 7:2001;4376-4387.
15. Cummings S.R., Eckert S.et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. results from the multiple outcomes of raloxifene evaluation (more) randomised trial JAMA. 281:1999;2189-2197.
16. Miwa M., Ura M., Nishida M.et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectivity in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 34:1998;1274-1281.
17. Blum J.L., Jones S.E., Buzdar A.U.et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 17:1999;485-493.
18. Reichardt P., Von Minckwitz G., Thuss-Patience P.et al. Multicenter phase II study of oral Capecitabine (Xeloda) in patients with metasatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol. 14:2003;1227-1233.
19. O'Shaughnessy J., Miles D., Vukelja S.et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer. phase III trial results J Clin Oncol. 20:2002;2812-2823.
20. Ranson M.R., Carmichael J., O'Bryne K.et al. Treatment of advanced breast cancer with sterically stabilised liosomal doxorubicin; results of a multicenter phase II trial. J Clin Oncol. 15:1997;3185-3191.
21. Keller A, Mennel R, Georgoulias V, et al. A randomized phase III trial of CAELYX/Doxil (pegylated liposomal doxorubicin HCL) versus standard salvage therapy in women with taxane-resistant advanced breast cancer. Ann Oncol 2003, in press.
22. Wigler N, Inbar M, O'Brien M, et al. Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (CAELYX/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 2002;45a (Abstract 177).
23. Vermoken J.B., Ten Bokkel Huinick W.W. Chemotherapy for advanced breast cancer. the place of active new drugs The Breast. 5:1996;304-311.
24. Slamon D.J., Clark G.M., Wong S.G.et al. Human breast cancer. correlation of relapse and survival with amplification of the HER-2/neu oncogene Science. 235:1987;177-182.
25. Vogel C., Cobleigh M.A., Tripathy D.et al. First-line, single agent Herceptin (trastuzumab) in metastatic breast cancer; a preliminary report. Eur J Cancer. 37:2001;25-29.
26. Slamon D., Leyland-Jones B., Shak S.et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER2. New Eng J Med. 344:2001;783-792.
27. Burstein H.J., Harris L.N., Marcom P.K.et al. Trastuzumab and vinorelbine as first line therapy for HER2-overexpressing metastatic breast cancer. multicenter phase ii trial with clinical outcomes, analysis of serum tumour markers as predictive factors, and cardiac surveillance algorithm J Clin Oncol. 21:2003;2889-2895.
28. Smith I.E. Future directions in the adjuvant treatment of breast cancer. the role of trastuzumab Ann Oncol. 12:2001;S75-S79.
29. Baselga J., Pfister D., Cooper M.R.et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 18:2000;904-914.
30. Nicholson R.I., Gee J.M. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer. 82:2000;501-513.
31. Druker B.J., Talpaz M., Resta D.et al. Efficacy and safety of a specific inhibitor of the BCR-abl tyrosine kinase in chronic myeloid leukaemia. N Engl J Med. 344:2001;1031-1037.
32. Ciardiello F., Caputo R., Bianco R.et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 6:2000;2053-2063.
33. Sirotnak F.M., Zakowski M.F., Miller V.A.et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 6:2000;4885-4892.
34. Bundred N.J., Chan K., Anderson N.G. Studies of epidermal growth factor inhibition in breast cancer. Endocrine-Related Cancer. 8:2001;183-189.
35. McClelland R.A., Barrow D., Madden T.A.et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology. 142(7):2001;2776-2788.
36. Knowlden J.M., Hutcheson I.R., Jones H.E.et al. Elevated levels of epidermal growth factor receptor/cerB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 144:2003;1032-1044.
37. Hutcheson I.R., Knowlden J.M., Madden T.et al. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat. 81:2003;81-93.
38. Ranson M., Hammond L.A., Ferry D.et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid malignant tumours; results of a phase I trial. J Clin Oncol. 20:2002;2240-2250.
39. Baselga J., Rischin D., Ranson M.et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumour types. J Clin Oncol. 20:2002;4292-4302.
40. Herbst R.S., Maddox A.M., Averbuch S.D. Selective oral epidermal growth factor receptor tyrsoine kinase inhibitor ZD1839 is generally well tolerated and has activity in non-small cell lung cancer and other solid tumours. results from a phase I study J Clin Oncol. 20:2002;3815-3825.
41. Kris M.G., Natale R.B., Herbst R.S.et al. A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer patients who had failed platinum and docetaxel regimens (IDEAL 2). Proc Am Soc Clin Oncol. 21:2002;292a. (A1166).
42. Fukuoka M, Yano S, Giaccone G. Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002;21:298a (Abstract 1188).
43. Baslega J., Albanelli J., Ruiz A.et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. Proc Am Soc Clin Oncol. 22:2003;A24.
44. Albain K., Elledge R., Gradishar W.J.et al. Open-label phase II multicenter trial of ZD1839 (Iressa) in patients with advanced breast cancer. Breast Cancer Res Treat. 76:2002;A20.
45. Robertson J.F.R., Gutteridge E., Cheung K.L.et al. Gefitinib (ZD1839) is active in acquired tamoxifen-resistant oestrogen receptor positive and ER-negative breast cancer. results from a phase II study Proc Am Soc Clin Oncol. 22:2003;A23.
46. Winer E., Cobleigh M., Dickler M.et al. Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 76:2002;A445.
47. Dancey J.E., Freidlen B. Targeting epidermal growth factor receptor - are we missing the mark? Lancet. 362:2003;62-64.
48. Jin W., Wu L., Liang K., Liu B., Lu Y., Fan Z. Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer. 89:2003;185-191.
49. Clark G.J., Der C.J. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat. 35:1995;133-144.
50. Kelland L.R., Smith V., Valenti M.et al. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res. 7:2001;3554-3560.
51. Johnston S.R.D., Hickish T., Ellis P.A.et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyltransferase inhibitor R115777 (Zarnestra) in patients with advanced breast cancer. J Clin Oncol. 21:2003;2492-2499.
52. Johnston S.R.D., Head J., Valenti M., Detre S., Dowsett M. Endocrine therapy combined with the farnesyltransferase inhibitor R115777 produces enhanced tumour growth inhibition in hormone-sensitive MCF-7 human breast cancer xenografts in-vivo. Breast Cancer Res Treat. 76:2002;A245.
53. Shi B., Yaremko B., Hajian G., Terracina G.et al. The farnesyl protein transferase inhibitor SCH66336 synergises with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol. 46:2000;387-393.
54. Sampath D., Plunkett W. Design of new anticancer therapies targeting cell cycle checkpoint pathways. Curr Opin Oncol. 13:2001;484-490.
55. Senderowicz A.M., Sausville E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst. 92:2000;376-387.
56. Yu K., Toral-Barza L., Discafani C.et al. mTOR, a novel target in breast cancer. the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocrine-Related Cancer. 8:2001;249-258.
57. Chan S., Scheulen M.E., Johnston S.R.D.et al. A phase II study of two dose levels of CCI-779 in locally advanced or metastatic breast cancer failing prior anthracyclines and/or taxanes regimens. Proc Am Soc Clin Oncol. 22:2003;A774.
58. Miles D.W., Towlson K.E., Graham R.et al. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer. 74:1996;1292-1299.
59. Folkman J. Tumor angiogenesis; therapeutic implications. N Engl J Med. 285:1971;1182-1186.
60. Gasparini G., Longo R., Sarmiento R., Morabito A. Inhibitors of cyclo-oxygenase 2. a new class of anticancer agents Lancet Oncol. 4:2003;605-615.